ProfileGDS5678 / 1437124_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 33% 32% 31% 32% 35% 31% 32% 35% 31% 32% 33% 35% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7546432
GSM967853U87-EV human glioblastoma xenograft - Control 22.7385233
GSM967854U87-EV human glioblastoma xenograft - Control 32.7284532
GSM967855U87-EV human glioblastoma xenograft - Control 42.6446131
GSM967856U87-EV human glioblastoma xenograft - Control 52.6867732
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8782935
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7429831
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7152232
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7686935
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6861831
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7228132
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.713233
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8050535
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6939131